Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety
Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro diagnostic test designed to detect and differentiate multiple high-risk viral infections in blood donations. Now accessible in countries recognizing the CE mark, this newly introduced assay represents a notable leap forward in the field of donor screening by enabling simultaneous detection of four major transfusion-transmissible viruses within a single, streamlined workflow.
The cobas MPX-E assay is engineered to identify and distinguish between Human Immunodeficiency Virus types 1 and 2 (HIV-1 and HIV-2), as well as Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Hepatitis E virus (HEV). By consolidating the screening of these pathogens into one integrated test, the assay addresses a long-standing need within blood screening laboratories for improved efficiency, accuracy, and operational simplicity. This unified approach not only reduces the complexity of testing protocols but also enhances the ability of healthcare providers to ensure the safety of blood and blood-derived products.
Blood safety remains a cornerstone of modern healthcare systems worldwide, particularly as demand for transfusions continues to rise due to surgical procedures, trauma care, chronic disease management, and oncology treatments. Ensuring that donated blood is free from infectious agents is critical to preventing the transmission of life-threatening diseases. In this context, Roche’s cobas MPX-E assay emerges as a powerful tool, offering laboratories the ability to perform comprehensive viral screening with improved turnaround times and reduced resource utilization.
According to Matt Sause, the launch of the assay reflects the company’s ongoing commitment to advancing diagnostic innovation and supporting healthcare systems globally. He emphasized that safe and timely access to blood products is fundamental to effective patient care. By introducing the cobas MPX-E test, Roche aims to provide laboratories with a fully integrated solution that not only targets the most clinically significant viral threats but also improves workflow efficiency and overall testing performance.
One of the most compelling aspects of the cobas MPX-E assay is its enhanced sensitivity and specificity, particularly in detecting Hepatitis E virus (HEV), an often-overlooked but increasingly recognized threat to blood safety. HEV is responsible for an estimated 20 million infections and approximately 70,000 deaths each year worldwide. A significant challenge in controlling HEV transmission is the fact that many infected individuals remain asymptomatic, making it difficult to identify carriers through conventional screening methods. As a result, nucleic acid-based testing has become an essential strategy for mitigating this risk.
The inclusion of HEV in the cobas MPX-E assay underscores Roche’s proactive approach to addressing emerging infectious threats. By enabling early and accurate detection of HEV in blood donations, the assay helps reduce the risk of transfusion-transmitted infections, particularly in vulnerable patient populations such as immunocompromised individuals, pregnant women, and those with pre-existing liver conditions.
In addition to its HEV capabilities, the assay incorporates advanced dual-target detection for HIV-1 group M, the most prevalent strain of HIV globally. This dual-target approach involves analyzing two independent regions of the viral genome, thereby increasing the likelihood of detecting the virus even in the presence of genetic mutations or variants. Such robustness is crucial in maintaining the reliability of test results, especially in the context of evolving viral landscapes where mutations can potentially compromise the performance of traditional diagnostic assays.
The cobas MPX-E assay is built on the principles of Nucleic Acid Testing (NAT), a highly sensitive methodology that detects viral genetic material rather than relying solely on antibody or antigen responses. NAT has become the gold standard in blood screening due to its ability to identify infections during the early “window period” before the immune system produces detectable antibodies. This early detection capability significantly reduces the risk of transmitting infections through blood transfusions.
From a market perspective, NAT-based blood screening represents a substantial and growing segment within the global diagnostics industry. Currently valued at approximately 800 million Swiss francs, the market is projected to expand at a compound annual growth rate (CAGR) of around 2% between 2024 and 2029. This steady growth reflects the increasing adoption of advanced molecular diagnostics, driven by rising awareness of blood safety, regulatory requirements, and technological advancements.
The operational efficiency of the cobas MPX-E assay is further enhanced by its compatibility with Roche’s established cobas x800 systems, including the cobas 6800/8800 and cobas 5800 platforms. These fully automated, high-throughput systems are already widely deployed in laboratories across the globe and collectively process more than 10 million tests each month. By leveraging this existing infrastructure, laboratories can seamlessly integrate the new assay into their workflows without the need for significant additional investment or retraining.
Automation plays a critical role in modern laboratory environments, where increasing test volumes and workforce constraints necessitate solutions that minimize manual intervention and maximize productivity. The cobas x800 systems are designed to deliver consistent, high-quality results while reducing the potential for human error. When combined with the multiplex capabilities of the MPX-E assay, these systems enable laboratories to achieve higher throughput with fewer resources, ultimately improving cost efficiency and service delivery.
Another important advantage of the cobas MPX-E assay lies in its ability to simplify laboratory operations. Traditionally, screening for multiple viruses required separate tests, each with its own reagents, protocols, and processing times. This fragmented approach not only increased operational complexity but also introduced potential delays and inefficiencies. By consolidating multiple targets into a single assay, Roche has effectively streamlined the testing process, allowing laboratories to optimize their workflows and allocate resources more effectively.
The introduction of the cobas MPX-E assay also aligns with broader trends in healthcare toward integrated and patient-centric solutions. As healthcare systems strive to improve outcomes while managing costs, there is a growing emphasis on technologies that enhance efficiency without compromising quality. Multiplex assays like MPX-E exemplify this approach by delivering comprehensive diagnostic insights in a single test, thereby supporting faster decision-making and improved patient care.
Furthermore, the assay’s availability in CE mark–accepting countries highlights Roche’s commitment to meeting stringent regulatory standards and ensuring that its innovations are accessible to a wide range of healthcare providers. The CE mark signifies compliance with European Union requirements for safety, health, and environmental protection, providing confidence to laboratories and clinicians regarding the reliability and performance of the assay.
In conclusion, the launch of the cobas MPX-E assay by Roche represents a significant milestone in the evolution of blood donor screening. By combining the detection of HIV-1, HIV-2, HBV, HCV, and HEV into a single, efficient workflow, the assay addresses critical challenges in laboratory diagnostics and enhances the safety of blood supplies worldwide. With its advanced molecular capabilities, compatibility with high-throughput automation platforms, and focus on emerging infectious threats, the cobas MPX-E assay is well positioned to play a pivotal role in safeguarding public health and supporting the delivery of high-quality healthcare services in the years to come.
About the cobas MPX-E assay
The cobas MPX-E assay is a multiplex real-time PCR test for the simultaneous detection and discrimination of HIV, HCV, HBV, and HEV in distinct channels. It is designed for use on the cobas x800 family of systems, offering a scalable solution that allows multiple tests to be run simultaneously at the same time. The assay offers flexible testing options, allowing laboratories to test for all four targets or select single targets based on their specific screening requirements. The ready-to-load reagents and automation allow for up to eight hours of walk-away time, freeing up laboratory staff for other critical tasks.
For laboratories currently screening for HEV, this assay offers faster turnaround times. For those looking to implement HEV screening, the cobas MPX-E provides a cost-effective solution that does not require additional floor space or instrumentation
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
Source Link:https://www.roche.com/
